Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (6090)	4/4/2002 4:48:28 PM
From: Jibacoa	Read Replies (1) \| Respond to of 52153

Peter: Thanks for the information. Do you know if the "<<as yet unknown proteins whose combined pattern of expression allows to discriminate between ca and non-ca.>>" is the same that were published in the article in Lancet ? Lancet 2002 Feb 16;359(9306):572-7 Their results yielded a sensitivity of 100% (95% CI 93--100) and a specificity of 95% (87--99) with a positive predictive value of 94% ncbi.nlm.nih.gov RAGL Bernard

To: Biomaven who wrote (6090)	4/4/2002 7:47:28 PM
From: quidditch	Read Replies (1) \| Respond to of 52153

<Please note that CIPH very likely does not have the rights to use their chips in clinical screening....> Peter, is that something that had not been clear when you expressed surprise and interest in CIPH's pr a few weeks ago that reported very strong sensitivity and specificity results. Is there "value" here where the business segments to be pursued are confined (if they are) to drug discovery and life sciences? Are the margins so high in sales of the chips that detect the cancer markers to players in those segments that it offsets what, to a layman, might seem as relatively lower volumes in those segments than would be the case for screening? quid